NO941877D0 - Type I og type II overflateantigener i forbindelse med Staphylococcus Epidermidis - Google Patents

Type I og type II overflateantigener i forbindelse med Staphylococcus Epidermidis

Info

Publication number
NO941877D0
NO941877D0 NO941877A NO941877A NO941877D0 NO 941877 D0 NO941877 D0 NO 941877D0 NO 941877 A NO941877 A NO 941877A NO 941877 A NO941877 A NO 941877A NO 941877 D0 NO941877 D0 NO 941877D0
Authority
NO
Norway
Prior art keywords
type
epidermidis
surface antigens
staphylococcus epidermidis
serotypes
Prior art date
Application number
NO941877A
Other languages
English (en)
Other versions
NO319013B1 (no
NO941877L (no
Inventor
Ali Ibrahim Fattom
Craig D Wright
Walter W Karakawa
Original Assignee
Univax Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univax Biolog Inc filed Critical Univax Biolog Inc
Publication of NO941877D0 publication Critical patent/NO941877D0/no
Publication of NO941877L publication Critical patent/NO941877L/no
Publication of NO319013B1 publication Critical patent/NO319013B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19941877A 1991-11-22 1994-05-19 Vaksine omfattende type I overflateantigener fra Staphylococcus epidermidis, samt hyperimmune globuliner og antistoff rettet mot type I-overflateantigenet. NO319013B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79625291A 1991-11-22 1991-11-22
PCT/US1992/009784 WO1993009811A1 (en) 1991-11-22 1992-11-20 TYPE I AND TYPE II SURFACE ANTIGENS ASSOCIATED WITH $i(STAPHYLOCOCCUS EPIDERMIDIS)

Publications (3)

Publication Number Publication Date
NO941877D0 true NO941877D0 (no) 1994-05-19
NO941877L NO941877L (no) 1994-06-16
NO319013B1 NO319013B1 (no) 2005-06-06

Family

ID=25167715

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19941877A NO319013B1 (no) 1991-11-22 1994-05-19 Vaksine omfattende type I overflateantigener fra Staphylococcus epidermidis, samt hyperimmune globuliner og antistoff rettet mot type I-overflateantigenet.

Country Status (12)

Country Link
US (2) US5866140A (no)
EP (1) EP0648127B1 (no)
JP (2) JP4087896B2 (no)
AT (1) ATE237351T1 (no)
AU (1) AU681573B2 (no)
CA (1) CA2123811C (no)
DE (1) DE69233012T2 (no)
DK (1) DK0648127T3 (no)
ES (1) ES2198405T3 (no)
FI (1) FI111336B (no)
NO (1) NO319013B1 (no)
WO (1) WO1993009811A1 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US7279162B1 (en) 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
US5955074A (en) * 1990-10-22 1999-09-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Directed human immune globulin for the prevention and treatment of staphylococcal infections
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
JP4160633B2 (ja) * 1994-09-21 2008-10-01 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン 共通のブドウ球菌抗原と広範に反応するオプソニン作用性抗体
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
WO2000012132A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
EP1121135B1 (en) * 1998-09-14 2009-01-28 Nabi Biopharmaceuticals Compositions of beta-glucans and specific immunoglobulins
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
WO2001034809A2 (en) * 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
US6703492B1 (en) 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins
CA2501077C (en) 2002-11-12 2016-06-21 Gerald B. Pier Polysaccharide vaccine for staphylococcal infections
WO2004043407A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
AU2005236068C1 (en) 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
EP2305294B1 (en) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
EP2298341A3 (en) 2004-10-21 2011-07-13 Wyeth LLC Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US20060153857A1 (en) * 2005-01-10 2006-07-13 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
CA2611023A1 (en) 2005-06-13 2006-12-21 Nabi Biopharmaceuticals Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
NZ574057A (en) 2006-06-12 2012-01-12 Glaxosmithkline Biolog Sa Staphylococcal antigen composition comprising an isolated S. aureus type 5 antigen; an isolated S. aureus type 8 antigen; an isolated S. aureus 336 antigen; an isolated S. aureus alpha-toxin antigen; and an isolated Staphylococcal leukocidin antigen
US7754225B2 (en) * 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection
AU2008280799B2 (en) * 2007-07-23 2013-07-11 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
RU2532911C2 (ru) 2008-07-21 2014-11-20 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам
JP2012530785A (ja) 2009-06-22 2012-12-06 ワイス・エルエルシー 組成物および黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）血清型５および８莢膜多糖コンジュゲート免疫原性組成物を調製するための方法
WO2010151544A1 (en) 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
JP5914344B2 (ja) 2009-10-30 2016-05-11 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ５型および８型の莢膜糖の精製
WO2012075428A1 (en) 2010-12-03 2012-06-07 Sanofi Pasteur Limited Composition for immunization against streptococcus pneumoniae
CN113730648B (zh) * 2021-09-06 2022-11-01 温州瑞司特生物科技有限公司 结合表皮葡萄球菌的水凝胶及其在治疗创面中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5452794A (en) * 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
FR2619122B1 (fr) * 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens

Also Published As

Publication number Publication date
JP4087896B2 (ja) 2008-05-21
FI942359A0 (fi) 1994-05-20
EP0648127B1 (en) 2003-04-16
ES2198405T3 (es) 2004-02-01
NO319013B1 (no) 2005-06-06
AU3074792A (en) 1993-06-15
EP0648127A1 (en) 1995-04-19
CA2123811C (en) 2005-07-05
FI942359A (fi) 1994-05-20
CA2123811A1 (en) 1993-05-27
DE69233012T2 (de) 2003-11-06
EP0648127A4 (en) 1995-06-14
US5866140A (en) 1999-02-02
FI111336B (fi) 2003-07-15
ATE237351T1 (de) 2003-05-15
AU681573B2 (en) 1997-09-04
DE69233012D1 (de) 2003-05-22
NO941877L (no) 1994-06-16
US5961975A (en) 1999-10-05
JPH07508498A (ja) 1995-09-21
DK0648127T3 (da) 2003-05-19
JP2004155789A (ja) 2004-06-03
JP4353789B2 (ja) 2009-10-28
WO1993009811A1 (en) 1993-05-27

Similar Documents

Publication Publication Date Title
NO941877L (no) Type I og type II overflateantigener i forbindelse med Staphylococcus Epidermidis
EP0077734A3 (en) Production of monoclonal antibodies against bacterial adhesins
ATE188708T1 (de) Antikörperderivate
ATE70309T1 (de) Menschliche monoklonale antikoerper gegen bakterielle toxine.
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
DK98187D0 (da) Monoklonale antistoffer og antigen for human ikke-smaacellet lungecarcinoma og visse andre typer human carcinoma
ATE7761T1 (de) Impfstoff und herstellungsverfahren.
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
EP0041897A3 (en) Polysaccharide antigen from streptococcus and vaccine containing the same
SE9000333D0 (sv) Monoklonal antikropp
YU22693A (sh) Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije
EP0327648A4 (en) HUMAN MONOCLONAL ANTIBODIES AND MEDICINES FOR PROPHYLAXIS AND TREATMENT OF INFECTIOUS DISEASES.
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
ATE207119T1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
ZA916313B (en) New use of a monoclonal antibody
ATE58061T1 (de) Verwendung von peptiden.
ATE110786T1 (de) Monoklonaler antikörper gegen exotoxin a von pseudomonas aeruginosa.
Lafon et al. Production of human monoclonal antibodies neutralizing rabies virus: An alternative to rabies immune globulin of human blood donation
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
BG51639A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody towards antigenous determinant of strain " hantaan " of the virus of haemorrhagic fever with nephritic syndrome
DK484688D0 (da) Fremgangsmaade til behandling af mastitis og andre staphylococcusinfektioner
DE68924963D1 (de) Zusammensetzungen und Methoden zur Behandlung und Vorbeugung von Gram-Negativen-Infektionen.
SU1565021A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus - продуцент моноклональных антител к вирусу ящура 0-01618
IT210111Z2 (it) Rete ombreggiante e rinfrescante per colture delicate.
RU92016461A (ru) Культура, линия клеток, моноклональные антитела, способ получения моноклональных антител, способ лечения, способ диагностики

Legal Events

Date Code Title Description
MK1K Patent expired